UBS Group
INM icon

UBS Group’s InMed Pharmaceuticals INM Stock Holding History

UBS Group’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,068
Closed -$5.2K – 10718
2026
Q1 		$5.2K Buy
8,068
+7,691
+2,040% +$7.25K ﹤0.01% 8820
2025
Q4 		$400 Buy
+377
New +$626 ﹤0.01% 9984
2025
Q3 		– Sell
-7,762
Closed -$25.2K – 10590
2025
Q2 		$25.2K Buy
7,762
+1,656
+27% +$4.59K ﹤0.01% 8292
2025
Q1 		$12.6K Sell
6,106
-4,302
-41% -$14.4K ﹤0.01% 8486
2024
Q4 		$49.3K Sell
10,408
-194
-2% -$937 ﹤0.01% 7305
2024
Q3 		$50.3K Buy
+10,602
New +$54K ﹤0.01% 6820
2024
Q2 		– Sell
-2
Closed -$15 – 9778
2024
Q1 		$15 Buy
+2
New +$15 ﹤0.01% 9062
2023
Q4 		– Sell
-3
Closed -$48 – 9586
2023
Q3 		$48 Buy
+3
New +$55 ﹤0.01% 9009
2023
Q2 		– Sell
-131
Closed -$2.83K – 9243
2023
Q1 		$2.83K Buy
131
+89
+212% +$2.88K ﹤0.01% 8433
2022
Q4 		$1.68K Sell
42
-248
-86% -$16.7K ﹤0.01% 9815
2022
Q3 		$38K Buy
+290
New +$53.6K ﹤0.01% 6612
2021
Q4 		– Sell
-10
Closed -$9K – 10466
2021
Q3 		$9K Buy
10
+6
+150% +$7.15K ﹤0.01% 8093
2021
Q2 		$7K Buy
4
+2
+100% +$3.1K ﹤0.01% 8331
2021
Q1 		$3K Buy
+2
New +$4.29K ﹤0.01% 8517

Other funds holding INM

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UFM
Ursa Fund Management Danville, California $1.28B AUM 89.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

UBS Group's INM Position: Q2 2026 in Review

UBS Group sold out of InMed Pharmaceuticals (INM) in Q2 2026, closing a stake of 8,068 shares — an estimated $5.2K sold.

UBS Group first reported a position in INM in Q1 2021 and held it in 14 quarters. The position peaked at $50.3K in Q3 2024. 20 funds tracked by Wall St. Rank hold INM as of Q2 2026.

  • UBS Group reported no remaining InMed Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 8,068 InMed Pharmaceuticals shares in Q2 2026, an estimated $5.2K.
  • UBS Group first reported a position in InMed Pharmaceuticals in Q1 2021 and held it in 14 quarters.
  • UBS Group's InMed Pharmaceuticals position peaked at $50.3K in Q3 2024.
  • 20 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.